-
-
-
-
-
-
-
Immunic names Erik Lundgren as new chief executive officer
-
-
-
-
-
-
-
D. Boral Capital Downgrades Immunic Inc. (IMUX) to Hold
-
-
-
-
-
-
-
Immunic Inc. (IMUX) Tops Q3 EPS by 2c
-
-
-
-
-
-
-
Immunic Inc. (IMUX) Misses Q2 EPS by 3c
-
-
-
-
-
-
-
Immunic Inc. (IMUX) Presents Key Vidofludimus Calcium Data
-
-
-
-
-
-
-
Immunic (IMUX) Reports Positive Outcome of Interim Analysis of Phase 3 ENSURE Program
-
-
-
-
-
-
-
Immunic Inc. (IMUX) Announces First Patient Enrolled in Investigator-Sponsored Phase 2 Clinical Trial of Vidofludimus Calcium in Patients with Post COVID Syndrome
-
483,138 total articles have been posted to this entity.
Click Here to Sign-Up for StreetInsider.com Premium to View All


